Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

Information provided by (Responsible Party):

University of Medicine and Dentistry New Jersey

ClinicalTrials.gov Identifier:

NCT00496366

First received: July 3, 2007

Last updated: June 13, 2012

Last verified: June 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2013
Estimated Primary Completion Date:	December 2013 (Final data collection date for primary outcome measure)